“It’s becoming more like cage fighting than company building.”
The Drug Delivery market is increasingly competitive. CEOs from the sector’s leading innovators Ocular Therapeutix, Kala Pharmaceuticals, Envisia Therapeutics and Icon Bioscience join in a discussion led by OIS Co-chair Emmett Cunningham, MD and K. Angela MacFarlane for ForSight Labs. Topics discussed including battling generics, protecting intellectual property and securing reimbursement. Kristin J. Havranek, an associate of Wilson Sonsini Goodrich & Rosati, shares insights on getting proper patent coverage that can help ensure survival.
Emmett T. Cunningham Jr., MD, PhD, MPH
Dr. Cunningham, currently a Partner, joined Clarus in 2006 with more than 20 years of experience in the biomedical and biopharmaceutical sectors.
K. Angela Macfarlane
Ms. Macfarlane brings over 20 years of experience in early stage company creation in both corporate and incubator settings to ForSight.
Amar Sawhney, PhD
Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the Board in 2014.
Mr. McDermott has 20 years of operating experience in the biotechnology and ophthalmology industries and currently serves as Kala’s Interim President and CBO.
David S. Tierney
David S. Tierney, M.D. is President and CEO of Icon Bioscience. Previously, Dr. Tierney was Co-Founder and President of Oceana Therapeutics, sold to Salix Pharmaceuticals in December 2011.
Benjamin Yerxa, PhD
Dr. Yerxa is President of Envisia Therapeutics, a spin out of Liquidia Technologies. Previously, he was the CSO for both Liquidia and Envisia and joined Liquidia from Clearside Biomedical.
Kristin J. Havranek
Kristin Havranek is a patent attorney at Wilson Sonsini Goodrich & Rosati, where she focuses on patent prosecution and technology counseling, with expertise in medical devices.